Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors α and β

Journal of Cellular Biochemistry

Volumn 89, Issue 3, 2003, Pages 633-646

  Rickard, D J ^a   Monroe, D G ^a   Ruesink, T J ^a   Khosla, S ^a   Riggs, B L ^a   Spelsberg, T C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alkaline phosphatase; Estrogen receptor; Genistein; IL 6; Osteoblasts; Osteoporosis; Phytoestrogens; Progesterone receptor; Versican

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; INTERLEUKIN 6; PHYTOESTROGEN; PROGESTERONE RECEPTOR; RALOXIFENE; VERSICAN;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NORTHERN BLOTTING; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR INTRINSIC ACTIVITY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CELL LINE, TRANSFORMED; DNA PRIMERS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION; GENISTEIN; HUMANS; INTERLEUKIN-6; OSTEOBLASTS; RALOXIFENE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

GLYCINE MAX; MAMMALIA;

EID: 0038360744     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10539     Document Type: Article

References (52)

1. Agnusdei D, Gennari C, Bufalino L. 1995. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporos Int 5:462-466.
2. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592-5595.
3. Alekel DL, St. Germain A, Peterson CT, Hanson KB, Stewart JW, Toda T. 2000. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72:844-852.
4. Arjmandi BH, Getlinger MJ, Goyal NV, Alekel L, Hasler CM, Juma S, Drum ML, Hollis BW, Kukreja SC. 1998. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 68:1358S-1363S.
5. Arjmandi BH, Birnbaum RS, Juma S, Barengolts E, Kukreja SC. 2000. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif Tissue Int 66:61-65.
6. Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casana R, Bufalino L, Serio M, Brandi ML. 1991. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 6:987-996.
7. Bode-Lesniewka B, Dours-Zimmermann MT, Odermatt BF, Briner J, Heitz PU, Zimmerman DR. 1996. Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 44:303-312.
8. Bryant HU, Glasebrook AL, Yang NN, Sato M. 1999. An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 69:37-44.
9. Cheng S-L, Zhange S-F, Nelson TL, Warlow PM, Civitelli R. 1994. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif Tissue Int 55:356-362.
10. Cooper C, Campion G. 1992. Hip fractures in the elderly: A world-wide projection. Osteoporos Int 2:285-289.
11. Deb S, Tessier C, Prigent-Tessier A, Barkai U, Ferguson Gottschall S, Srivastava RK, Faliszek J, Gibori G. 1999. The expression of interleukin-6 (IL-6), IL-6 receptor, and gp-130-Kilodalton glycoprotein in the rat decidua and a decidual cell line: Regulation by 17β-estradiol and prolactin. Endocrinology 140:4442-4450.
12. Dours-Zimmermann MT, Zimmerman DR. 1994. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 269:32992-32998.
13. Evans GL, Bryant HU, Magee DE, Turner RT. 1996. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137:4139-4144.
14. Gennari C, Adami S, Agnusdei D, Bufalino L, Cervetti R, Crepaldi G, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Mazzuoli GF, Ortolani S, Passeri M, Serni U, Vecchiet L. 1997. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 61:S19-S22.
15. Giossi M, Caruso P, Civelli M, Bongrani S. 1996. Inhibition of parathyroid hormone-stimulated resorption in cultured fetal rat long bones by the main metabolites of ipriflavone. Calcif Tissue Int 58:419-422.
16. Glazier MG, Bowman MA. 2001. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 161:1161-1171.
17. Harris SA, Tau KR, Enger RJ, Toft DO, Riggs BL, Spelsberg TC. 1995. Estrogen response in hFOB1.19 human fetal osteoblastic cell line stably transfected with the human estrogen receptor gene. J Cell Biochem 59: 193-201.
18. Jilka RL, Hangoc G, Girasole G, Passeri M, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. 1992. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88-91.
19. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. 1990. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different progesterone receptor forms A and B. EMBO J 9:1603-1614.
20. Kimata K, Oike Y, Tani K, Shinomura T, Yamagata M, Uritani M, Suzuki S. 1986. A large chondroitin sulfphate proteoglycan (PG-M) synthesized before chondrogenesis in the limb bud of chick embryo. J Biol Chem 261:13517-13525.
21. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson J-A. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263.
22. LeBaron RG, Zimmerman DR, Ruoslahti E. 1992. Hyaluronate binding properties of versican. J Biol Chem 267: 10003-10010.
23. MacNamara P, Loughrey HC. 1998. Oestrogen regulates the expression of progesterone receptor A and B isoforms in human osteoblast cells. Calcif Tissue Int 63:39-45.
24. Notoya K, Yoshida K, Taketomi S, Yamazaki I, Kumegawa M. 1993. Inhibitory effect of ipriflavone on osteclastmediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cells. Calcif Tissue Int 53:206-209.
25. Nuttall ME, Stroup GB, Fisher PW, Nadeau DP, Gowen M, Suva LJ. 2000. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells. Am J Physiol Cell Physiol 279:C1550-C1557.
26. Oursler MJ. 1998. Estrogen regulation of gene expression in osteoblasts and osteoclasts. Crit Rev Euk Gene Expr 8:125-140.
27. Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, Kennedy MB, Pockwinse S, Lian JB, Stein GS. 1990. Progressive development of the rat osteoblasts phenotype in vitro: Reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 143:420-430.
28. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS. 1997. Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites. Science 277:1508-1510.
29. Passeri M, Biondi M, Costi D, Bufalino L, Castiglione GN, Di Peppe C, Abate G. 1992. Effect of ipriflavone on bone mass in elderly osteoporotic women. Bone Miner 19:S57-S62.
30. Passeri G, Girasole G, Jilka RL, Manolagas SC. 1993. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 133:822-828.
31. Perissinotto D, Iacopetti P, Bellina I, Doliana R, Colombatti A, Pettway Z, Bronner-Fraser M, Shinomura T, Kimata K, Morgelin M, Lofberg J, Perris R. 2000. Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/versican and aggrecan. Development 127:2823-2842.
32. Picherit C, Bennetau-Pelissero C, Chanteranne B, Lebecque P, Davicco M-J, Barlet J-P, Coxam V. 2001. Soybean isoflavones dose-dependently reduce bone turnover but do not reverse established osteopenia in adult ovariectomized rats. J Nutr 131:723-728.
33. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JWJ. 1998. Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68:1375S-1379S.
34. Rickard DJ, Hofbauer LC, Bonde SK, Gori F, Spelsberg TC, Riggs BL. 1998. Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. J Clin Invest 101:413-422.
35. Rickard DJ, Waters KM, Ruesink TJ, Khosla S, Katzenellenbogen JA, Katzenellenbogen BS, Riggs BL, Spelsberg TC. 2002. Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J Bone Miner Res 17:580-592.
36. Robey PG, Boskey AL. 1996. The biochemistry of bone. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego, CA; Academic Press, Inc. pp 95-183.
37. Robinson JA, Harris SA, Riggs BL, Spelsberg TC. 1997. Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138:2919-2927.
38. Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL, Cheresh DA. 1993. Interaction between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha V beta 3 potentiate bone resorption. J Biol Chem 268:9901-9907.
39. Russell-Aulet M, Wang J, Thornton JC, Colt EW, Pierson RNJ. 1993. Bone mineral density and mass in a crosssectional study of white and Asian women. J Bone Miner Res 8:575-582.
40. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson J-A, Safe S. 2000. Ligand-, cell-, and estrogen receptor subtype (α/β)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379-5387.
41. Schonherr E, Kinsella MG, Wight TN. 1997. Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch Biochem Biophys 339:353-361.
42. Shinomura T, Jensen KL, Yamagata M, Kimata K, Solursh M. 1990. The distribution of mesenchyme proteoglycan (PG-M) during wing bud outgrowth. Anat Embryol 181: 227-233.
43. Stein B, Yang MX. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol Cell Biol 15:4971-4979.
44. Turner RT, Colvard DS, Spelsberg TC. 1990. Estrogen inhibition of periosteal bone formation in rat long bone: Down regulation of gene expression for bone matrix proteins. Endocrinology 127:1346-1351.
45. Uesugi T, Toda T, Tsuji K, Ishida H. 2001. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones, Daidzin, genistin and glycitin. Biol Pharm Bull 24:368-372.
46. Wakeling AE, Valcaccia B, Newboult E, Green LR. 1984. Non-steroidal antioestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma cells and human breast cancer cells. J Steroid Biochem Mol Biol 20:111-120.
47. Waters KM, Rickard DJ, Riggs BL, Khosla S, Katzenellenbogen JA, Katzenellenbogen BS, Moore J, Spelsberg TC. 2001. Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. J Cell Biochem 83:448-462.
48. Wronski TJ, Cintron M, Doherty AL, Dann LM. 1988. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123:681-686.
49. Yamagishi T, Otsuka E, Hagiwara H. 2001. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: Evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 142:3632-3637.
50. Yamaguchi M, Sugimoto E. 2000. Stimulatory effect of genistein and daidzein on protein synthesis in osteoblastic MC3T3-E1 cells: Activation of aminoacyl-tRNA synthetase. Mol Cell Biochem 214:97-102.
51. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. 1996. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 273:1222-1225.
52. Zimmermann DR, Ruoslahti E. 1989. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 8: 2975-2981.